IP Library Granted Patent US 7,521,045
Granted Patent B2
US 7,521,045 · App. 11/197,711 · Granted Apr 21, 2009

Methods of inhibiting metastasis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,521,045
App. No.
11/197,711
Granted
Apr 21, 2009
Kind
B2
Abstract

Methods of inhibiting metastasis or maintenance of various cancers are provided. In particular, the method makes use of fact that certain trafficking of cancers depend upon identified proteins, which serve as markers. Additional methods of screening are also provided.

Claims (32)

1. A method for reducing metastasis of a head and neck cancer cell in a subject comprising

administering an effective amount of anti-CXCR4 antibody or CXCR4 receptor-binding fragment thereof to the subject.

2. The method of claim 1 , wherein said metastasis is organ specific.

3. The method of claim 1 , wherein said metastasis is to a lymph node, bone marrow, or skin.

4. The method of claim 1 , wherein the subject is further administered pertussis toxin.

5. The method of claim 1 , wherein the subject is further administered another anti-cancer treatment.

6. The method of claim 5 , wherein said anti-cancer treatment is administered before said antibody is administered.

7. The method of claim 5 , wherein said anti-cancer treatment is chemotherapy.

8. The method of claim 5 , wherein said anti-cancer treatment is radiation therapy.

9. The method of claim 5 , wherein said anti-cancer treatment is immunotherapy.

10. The method of claim 5 , wherein said anti-cancer treatment is surgery.

11. A method for reducing metastasis of a head and neck cancer cell in a subject comprising

administering an effective amount of anti-SDF-1 antibody or SDF-1 ligand-binding fragment thereof to the subject.

12. The method of claim 11 , wherein said metastasis is organ specific.

13. The method of claim 11 , wherein said metastasis is to a lymph node, bone marrow, or skin.

14. The method of claim 11 , wherein the subject is further administered pertussis toxin.

15. The method of claim 11 , wherein the subject is further administered another anti-cancer treatment.

16. The method of claim 15 , wherein said anti-cancer treatment is administered before said antibody is administered.

17. The method of claim 15 , wherein said anti-cancer treatment is chemotherapy.

18. The method of claim 15 , wherein said anit-cancer treatment is radiation therapy.

19. The method of claim 15 , wherein said anti-cancer treatment is immunotherapy.

20. The method of claim 15 , wherein said anti-cancer treatment is surgery.

21. The method of claim 1 wherein the subject is human.

22. The method of claim 11 wherein the subject is human.

23. The method of claim 1 wherein the antibody or receptor-binding fragment is further administered with one or more therapeutics selected from the group consisting of an alkylating agent, an antimetabolite, an anti-hormone, a painkiller, a diuretic, an antidiuretic, an antiviral, an antibiotic, a nutritional supplement, an anti-anemia therapeutic, a blood clotting therapeutic, a bone therapeutic and a psychological therapeutic.

24. The method of claim 11 wherein the antibody or ligand-binding fragment is further administered with one or more therapeutics selected from the group consisting of an alkylating agent, an antimetabolite, an anti-hormone, a painkiller, a diuretic, an antidiuretic, an antiviral, an antibiotic, a nutritional supplement, an anti-anemia therapeutic, a blood clotting therapeutic, a bone therapeutic and a psychological therapeutic.

25. The method of claim 1 wherein the antibody is administered at weekly dosage of at least 10 micrograms/kg body weight.

26. The method of claim 11 wherein the antibody is administered at weekly dosage of at least 1 mg/kg body weight.

27. The method of claim 23 wherein the therapeutic is an alkylating agent or an antimetabolite.

28. The method of claim 24 wherein the therapeutic is an alkylating agent or an anti-metabolite.

29. The method of claim 1 for reducing metastasis of a head and neck cancer cell in a human subject comprising administering an effective amount of anti-CXCR4 monoclonal antibody to the subject.

30. The method of claim 11 for reducing metastasis of a head and neck cancer cell in a human subject comprising administering an effective amount of anti-SDF-1 monoclonal antibody to the subject.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →